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Abstract: To facilitate efficient drug delivery to tumor tissue, several nanomaterials have 
been designed, with combined diagnostic and therapeutic properties. In this work, we 
carried out fundamental in vitro and in vivo experiments to assess the labeling efficacy of 
our novel theranostic nanoprobe, consisting of glycogen conjugated with a red fluorescent 
probe and gadolinium. Microscopy and resazurin viability assays were used to study cell 
labeling and cell viability in human metastatic melanoma cell lines. Fluorescence lifetime 
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correlation spectroscopy (FLCS) was done to investigate nanoprobe stability. Magnetic 
resonance imaging (MRI) was performed to study T1 relaxivity in vitro, and contrast 
enhancement in a subcutaneous in vivo tumor model. Efficient cell labeling was 
demonstrated, while cell viability, cell migration, and cell growth was not affected. FLCS 
showed that the nanoprobe did not degrade in blood plasma. MRI demonstrated that down 
to 750 cells/μL of labeled cells in agar phantoms could be detected. In vivo MRI showed 
that contrast enhancement in tumors was comparable between Omniscan contrast agent  
and the nanoprobe. In conclusion, we demonstrate for the first time that a non-toxic 
glycogen-based nanoprobe may effectively visualize tumor cells and tissue, and, in future 
experiments, we will investigate its therapeutic potential by conjugating therapeutic 
compounds to the nanoprobe. 
Keywords: melanoma brain metastasis; nanoprobe; theranostics; magnetic resonance 
imaging; fluorescence microscopy; high throughput microscopy; fluorescence lifetime 
correlation spectroscopy; zeta potential 
 
1. Introduction 
Around 90% of cancer patients die of tumor metastasis [1]. A detailed and accurate diagnosis of 
cancer metastasis is therefore necessary in the management of metastatic disease [2]. Commonly used 
imaging techniques in the clinic, such as magnetic resonance imaging (MRI), computerized 
tomography (CT) and positron emission tomography (PET), play a critical role in diagnosis and 
therapy of cancer metastasis [2–4]. A combined use of imaging modalities (i.e., multimodal imaging) 
has the potential of combining anatomical and physiological image information, thereby improving our 
understanding of tumor development and therapeutic responses [5,6]. 
Recently, increased attention has been given to the establishment of functional nano-scaled materials for 
the application of combined cancer therapy and diagnostics, also named “nano-theranostics” [7–9]. By 
using such systems, multimodal imaging is able to confirm delivery of therapeutic substances to the 
tumors and provides a superior visualization of treatment efficacy by real-time monitoring of treatment 
response [10,11]. An ideal nanoscale drug delivery platform should be biodegradable and non-toxic. 
The drug load should also occur locally within tumor tissue and reach therapeutic concentrations for a 
sufficient period of time [12]. Recent developments have advanced the use of theranostic nanomaterials on 
neoplasms also within the central nervous system (CNS), which may improve treatment of brain 
metastatic disease in future [13,14]. Polysaccharide-based nanomaterials have drawn notable attention, 
as they are biocompatible in vivo and have the potential to traverse physiological obstacles [15–18]. 
Further, optimization of size and surface coating of the nanomaterial may extend the circulation  
time after intravenous administration compared to standard delivery methods of chemotherapeutic 
drugs [19]. Moreover, solid tumors spontaneously accumulate biocompatible polymers, polymer 
micelles, liposomes and nanoparticles less than 200 nm in diameter due to the leaky nature of the 
newly formed tumor neovasculature. This enhanced permeability and retention (EPR) effect is 
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relatively universal for many solid tumors and allows concentrating nanoparticles to more than one 
order of magnitude compared to surrounding tissue [20,21]. 
We have recently developed a nanoprobe for multimodal imaging, composed of glycogen 
conjugated with gadolinium (Gd-DOTA) and the red fluorescent marker Dyomics-615-NHS  
(Dy-615) [22]. D-Glucose is normally stored as glycogen in the human body (for instance in muscle 
and liver tissue), and the use of glycogen as the backbone of a nanoprobe offers several advantages.  
It is biodegradable and non-toxic to human cells. Furthermore, the abundance, low cost, and wide 
range of modification possibilities makes glycogen attractive for use in an imaging nanoprobe. 
We report here for the first time the application of a glycogen nanoprobe, used to image tumor cells. 
We demonstrate that the nanoprobe effectively labeled human metastatic melanoma cells in vitro, and 
cellular properties such as viability and migration was not affected after labeling. T1 weighted in vivo 
MRI scans showed that the contrast enhancement in subcutaneous tumors obtained by the nanoprobe 
was comparable to using a contrast agent commonly used in the clinic. Our data suggest that the 
nanoprobe may likely accumulate in solid tumor tissue due to the EPR effect. The nanoprobe may 
easily be expanded to a nano-theranostic entity, by conjugating it with a therapeutic substance. The 
main aim of this study was, however, to show proof-of-principle that the nanoprobe is an effective 
contrast agent for multimodal imaging, while future experiments will address its theranostic utility, 
where therapeutic agents will be conjugated to the nanoprobe, and the in vivo effects will be studied in 
our mouse models of metastatic melanoma. 
2. Results and Discussion 
2.1. The Glycogen Nanoprobe Is Efficiently Internalized into the Metastatic Melanoma Cell Lines 
We first evaluated the uptake of the glycogen nanoprobe into H1_DL2 human melanoma metastatic 
cells and two normal human fibroblast cell lines (SV-80 and NSF3) by intracellular fluorescence 
intensity from Dy-615 after labeling the cells with nanoprobe doses ranging from 10 to 100 μg/mL 
(Figure 1A). After 6 h, H1_DL2 cells incubated with 10 μg/mL nanoprobe had internalized a minor 
amount of the nanoprobe. Increased concentration of labeling solution resulted in increased uptake of 
nanoprobe, as seen by elevated fluorescence intensity. Further, incubation for 24 h with the same 
concentrations showed stronger uptake of the nanoprobe (Figure 1A). We could not detect any  
uptake of nanoprobe into the two fibroblast cell lines, even at a labeling concentration of 100 μg/mL  
(Figure S1). 
A detailed inspection of the fluorescence images revealed that all the cells were labeled already 
when using 10 μg/mL of the nanoprobe. However, a rather weak fluorescence was observed for all 
labeling concentrations, except 100 μg/mL, indicating that higher concentrations should also be evaluated. 
Therefore, we increased the labeling concentrations of nanoprobe to between 100–400 μg/mL. 
Micrographs obtained from live-cell high-throughput imaging indicated that during an incubation time 
of 24 h all of the cells were effectively and strongly labeled at these concentrations (Figure 1B). The 
fluorescence intensities from the micrographs were then quantified (Figure 1C–E). In general, there 
was a dose-dependent as well as a time-dependent increase in mean fluorescence intensities for all cell 
lines. For the H1_DL2 cells (Figure 1C) and the Melmet 5 pGFI cells (Figure 1E), a statistically 
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significant increase in fluorescence was seen after increasing the labeling concentration to 200 μg/mL. 
For the Melmet 1 pGF1 cells (Figure 1D), there was no increase in labeling efficacy in the range of 
100 to 300 μg/mL (24 h labeling time). Based on these results, we continued to investigate cell 
viability using a nanoprobe labeling concentration of 200 μg/mL. 
 
Figure 1. Cellular uptake of the glycogen nanoprobe. (A) Fluorescence micrographs 
overlaid light microscopy images, showing the H1_DL2 cells after being labeled with the 
glycogen nanoprobe for 6 or 24 h. Scale bar, 100 μm; (B) Representative fluorescence 
micrographs, showing the H1_DL2 cells after being labeled with the glycogen nanoprobe 
for 2, 4, 6 or 24 h. Similar high throughput experiments were performed for all three cell 
lines. Scale bar: 100 μm; (C–E) Quantification of mean fluorescence intensity in the 
images acquired of the three cell lines by high throughput microscopy. ns: not significant; 
* p < 0.05; ** p < 0.01: (C) H1_DL2 cell line; (D) Melmet 1 pGF1 cell line; and  
(E) Melmet 5 pGF1 cell line. 
2.2. The Glycogen Nanoprobe Does Not Affect Short-Term Cell Viability in Vitro 
The survival of cells labeled with 200 μg/mL glycogen nanoprobe was studied using a resazurin 
viability assay (Figure 2A). From 72 h onwards, Melmet 1 pGF1 cells showed reduced proliferative 
capacity compared to the unlabeled cell population. This was also seen for Melmet 5 pGF1 cells 
labeled with 200 μg/mL after 24 h. However, subsequent measurements showed no significant 
differences at later time points. H1_DL2 cells did not show decreased viability until 120 h of exposure 
to the glycogen nanoprobe (Figure 2A). 
Viability was also assessed by counting live and dead cells, after incubation with 200 μg/mL 
glycogen nanoprobe for up to 72 h. We found no significant differences in viability between labeled 
and unlabeled cells for any of the cell lines (Figure 2B–G). Thus, based on the internalization and 
viability studies, a labeling time of 24 h using a concentration of 200 μg/mL nanoprobe was chosen for 
subsequent experiments. 
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Figure 2. Cell viability in monolayer cultures. (A) Monolayer resazurin assay to determine 
viability of labeled and unlabeled melanoma metastatic cell lines for 120 h. The labeled 
cells were exposed to 200 μg/mL of the glycogen nanoprobe during the whole time period 
(for all experiments, n = 8; mean ± SD). The relative fluorescence units (vertical axis) were 
proportional to the number of viable cells. * p < 0.05, ** p < 0.01, **** p < 0.0001;  
(B–D) Cell counting assay to determine the number of viable cells in monolayer cultures of 
labeled and unlabeled cell lines during 72 h. The labeled cells were exposed to 200 μg/mL 
of the glycogen nanoprobe during the whole time period (for all experiments, n = 6;  
mean ± SD): (B) H1_DL2 cells; (C) Melmet 1 pGF1 cells; and (D) Melmet 5 pGF1 cells;  
(E–G) Cell counting assay to determine the number of dead cells in monolayer cultures of 
labeled and unlabeled cell lines during 72 h. The labeled cells were exposed to 200 μg/mL 
of the glycogen nanoprobe during the whole time period (for all experiments, n = 6;  
mean ± SD): (E) H1_DL2 cells; (F) Melmet 1 pGF1 cells; and (G) Melmet 5 pGF1 cells. 
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2.3. The Glycogen Nanoprobe Is Localized in Cytoplasm and Lysosomes 
To investigate the subcellular localization of the nanoprobe, H1 human metastatic melanoma cells 
were labeled with the nanoprobe and incubated with markers for different cellular organelles (Figure 3, 
Table 1). In general, the nanoprobe was localized within the cytoplasm of the cells. Our analysis 
showed that the only organelle able to internalize the nanoprobe were the lysosomes (Figure 3C,  
R = 0.5614). All other organelles investigated had a random co-distribution with the nanoprobe, and no 
co-localization could be detected (R < 0.5, Table 1). 
 
Figure 3. Internalization of the glycogen nanoprobe into organelles within the H1 cells.  
All organelle probes were conjugated to a green fluorescent dye (top row, A–E) or 
Hoechst (F), while the red fluorescent probe Dyomics-615 was incorporated into the 
nanoprobe (middle row, A–F). In order to determine co-localization of the nanoprobe with 
the organelles and thus showing internalization, the red fluorescent images were overlaid 
the green fluorescent images (bottom row, A–E) or the Hoechst (blue) images (bottom 
row, F). (A) Staining of Golgi apparatus using the CytoPainter Golgi Staining Kit 
(Abcam); (B) staining of mitochondria using MitoTracker Green (Invitrogen); and (C) 
staining of lysosomes using CytoPainter LysoGreen (Abcam). Areas of co-localization 
(yellow areas in the overlay picture) could be found; (D) Staining of membranes using 
Wheat Germ Agglutinin Alexa Fluor Conjugate (Thermo Fisher Scientific); (E) staining of 
endoplasmic reticulum using the CytoPainter ER Staining Kit (Abcam); and (F) staining of 
nuclei using Hoechst 33342 (Life Technologies). Scale bar, 10 μm. 
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Table 1. Co-localization of nanoprobe to organelles. 
Organelle 
Mean Pearson’s 
Correlation Coefficient 
n SD 
Golgi apparatus 0.0283 2 0.0063 
Mitochondria 0.0574 1 0 
Lysosome 0.5614 5 0.0849 
Plasma membrane 0.0166 5 0.1003 
Endoplasmatic reticulum 0.2839 3 0.0535 
Nucleus 0.1117 11 0.2049 
2.4. Intracellular Glycogen Nanoprobe Can Be Detected up to 96 h after Labeling 
Nanoprobe clearance was assessed by measuring the decrease in cellular fluorescence intensity over 
96 h, after an incubation period of 24 h with 200 μg/mL nanoprobe (Figure 4). In general, the cellular 
fluorescence intensity declined with increased time (Figure 4A,C). Cellular fluorescence within the 
cells was measured after outlining the cells, as shown in Figure 4B. In total, 64 cells were measured at 
each time point for each cell line, and the mean intensity value was calculated. This analysis verified a 
gradual decrease in fluorescence intensity for all cell lines over a time period of 96 h (Figure 4C). 
However, around 9% of the nanoprobe was still internalized at that time point. Our study showed an 
inverse relationship between cell proliferation (Figure 4D) and clearance (Figure 4C), indicating an 
elevated dilution of nanoprobe in more rapidly proliferating cell lines. 
2.5. Labeling with the Glycogen Nanoprobe Does Not Influence in Vitro Cell Migration 
To study whether labeling with the nanoprobe affected cell migration, a standardized monolayer 
wound healing assay was carried out (Figure 5). Labeled and unlabeled Melmet 1 pGF1 cells 
demonstrated similar wound healing capacities, and cell labeling did not influence migration  
(Figure 5A,B). The wound was closed after 18 h, both for labeled and unlabeled cells (Figure 5D). 
Similar results were also found for the H1_DL2 and Melmet 5 pGF1 cell lines (Figure 5C,E), as there 
were no differences in migration between labeled and unlabeled cells. The wounds were closed after 
45 h for the H1_DL2 cells, while 15% of the initial area was still open after 45 h for the Melmet 5 
pGF1 cell line. 
 
Figure 4. Cont. 
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Figure 4. Clearance of the glycogen nanoprobe from cells after removing the labeling 
solution. (A) Representative micrographs demonstrating a gradual decrease in cellular 
fluorescence intensity for H1_DL2 (top row), Melmet 1 pGF1 (middle row) and Melmet 
5 pGF1 (bottom row) cells during four days in culture. Scale bar: 50 μm; (B) For each 
time point, the cellular area of 64 cells (from each cell line) was outlined in Photoshop, as 
shown in this example. Scale bar: 10 μm; (C) The mean fluorescence intensity for each cell 
was determined, and the mean values of all 64 cells were calculated and plotted for each 
time point (mean ± SD); (D) Cell proliferation for each cell line was determined over a 
time period of 72 h (mean ± SD). The curves were obtained by linear regression (Graphpad 
Prism v6). 
 
Figure 5. In vitro wound healing assay to determine migration capacity. (A) Melmet 1 
pGF1 cells labeled with 200 μg/mL of nanoprobe; (B) unlabeled Melmet 1 pGF1 cells;  
(C) quantification of open wound area of unlabeled and labeled H1_DL2 cells for 45 h;  
(D) quantification of open wound area of unlabeled and labeled Melmet 1 pGF1 cells for 
24 h; and (E) quantification of open wound area of unlabeled and labeled Melmet 5 pGF1 
cells for 45 h. Scale bar: 100 μm; (C–E) n = 8, mean ± SD. ns: not significant. 
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2.6. The Surface Charge of the Nanoprobe Is Minimally Affected by pH 
The subcellular uptake of the glycogen nanoprobe (Figure 3) could in theory be affected by changes 
in its surface charge, due to differences in pH within the different cytosolic compartments. Therefore, 
we measured the zeta-potential of the nanoprobe as a function of pH. We found that the zeta-potential 
of the glycogen nanoprobe was slightly positive and decreased with increasing pH (obtained values of 
zeta-potential were 16.7 ± 0.85, 13.8 ± 0.72, 7.28 ± 0.47 and 5.10 ± 0.74 mV, for pH 5.03, 6.00, 6.99 
and 7.39, respectively). This can be explained by presence of unreacted amino groups. 
2.7. The Nanoprobe Is Stable in Blood Plasma for at Least 60 min 
We measured nanoprobe stability over time by fluorescence lifetime correlation spectroscopy 
(FLCS). In general, our results consistently indicated that the glycogen nanoparticles were stable for at 
least 60 min in human blood plasma. 
We first measured the labeled glycogen in physiological saline, and obtained a recovered diffusion 
constant of about 4 μm2/s, which is around two orders of magnitude lower than what a free dye of the 
size of Dy-615 would have in water. A closer inspection of the FLCS curve revealed that there was a 
small fraction of faster diffusing particles, with a diffusion coefficient D around 30–40 μm2/s, likely 
due to a fraction of unbound Dy-615 diffusing in the solution. That means that a small fraction of  
Dy-615 was non-covalently linked to the glycogen particles and preserved partly its mobility. 
We then measured pure human blood plasma, and showed that the autofluorescence intensity  
after 640 nm laser excitation was very small, less than 5% of the intensity of labeled glycogen  
under the same conditions, and could therefore be neglected in the subsequent measurements of  
plasma–glycogen mixtures. The average diffusion coefficient was around 60 μm2/s. 
The labeled glycogen and blood plasma were then mixed directly in a one-chamber microscope 
dish, and FLCS was performed. The observed diffusion clearly consisted of two major components. 
One component was practically identical to the major component of the labeled glycogen in 
physiological saline (D around 4 μm2/s). The other component was faster with a diffusion constant 
similar to plasma (D around 60 μm2/s), and was likely due to a non-covalently linking of a small  
Dy-615 fraction released from the labeled glycogen to plasma proteins (as seen in saline). 
Most importantly, the diffusion of the glycogen nanoparticles themselves (fraction with diffusion 
constant of about 4 μm2/s) did not show any change during 60 min after mixing. 
2.8. The Glycogen Nanoprobe Is an Effective Contrast Agent in Vitro 
To study whether cell labeling with the glycogen nanoprobe reduced the T1 relaxation times, we 
conducted an in vitro relaxometry experiment with MRI phantoms (Figure 6A). For Melmet 1 pGF1 
cells, we detected a statistically significant reduction in T1 relaxation times for labeled cells  
(with 200 μg/mL nanoprobe) down to 750 cells/μL, as compared to the phantoms with unlabeled cells. 
For phantoms with H1_DL2 and Melmet 5 pGF1 cells, labeled cells reduced the T1 relaxation down to 
cell concentrations of 1500 cells/μL, as compared to the control phantoms (Figure 6A). The data also 
suggested that a concentration of 750 cells/μL of labeled H1_DL2 and Melmet 5 pGFI cells could 
reduce the relaxation times, however this was not statistically significant. 
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Figure 6. In vitro relaxometry and in vivo tumor imaging. (A) T1 relaxation times for 
phantoms containing labeled and unlabeled H1_DL2 cells (left), labeled and unlabeled 
Melmet 1 pGF1 cells (middle), and labeled and unlabeled Melmet 5 pGF1 cells (right). 
The different cell concentrations used are shown on the horizontal axis. Mean ± SD, n = 3. 
* p < 0.05; ** p < 0.01; ms: milliseconds; (B) Representative bioluminescence image of 
tumor growth in one of the NOD/SCID mice four weeks after injection of H1_DL2 cells in 
the neck and flank area; (C) Representative axial MR images of the neck tumors in the 
same mouse as shown in (B), eight weeks after tumor cell injection. T2 weighted image 
(left), T1 weighted image before contrast injection (middle), and T1 weighted image after 
injecting Omniscan (right); (D) Magnetic resonance (MR) images of the same mouse as in 
(C), using the nanoprobe as contrast agent. T2 weighted image (left), T1 weighted image 
before contrast injection (middle), and T1 weighted image after injecting nanoprobe (right). 
Scale bar, 5 mm. 
2.9. The Glycogen Nanoprobe Effectively Enhances MRI T1 Contrast in Subcutaneous Tumors 
Tumor take and development was verified by bioluminescence imaging (BLI) four weeks after 
subcutaneous injection of H1_DL2 cells into the mice, and tumor necrosis was not observed at that 
time point (Figure 6B). T2 weighted MRI images acquired eight weeks after tumor cell injections 
showed tumor edema and necrotic areas within the tumors (Figure 6C-left, Figure 6D-left). 
Administration of Omniscan showed enhanced tumor contrast on T1 weighted images (Figure 6D-right), 
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most likely due to leaky tumor blood vessels, compared to T1 weighted images obtained before 
contrast injections (Figure 6D-middle). In addition, contrast enhancement of the tumors on T1 
weighted scans was clearly detected after administration of the nanoprobe (Figure 6D-middle, right). 
We then used the T1 weighted images to calculate the contrast noise ratio (CNR) in tumor versus 
normal tissue adjacent to the tumor on two mice scanned with both contrast agents. We found that the 
mean CNR value was 42.8 after administration of Omniscan, and 49.5 after administration of the 
glycogen nanoprobe. This indicated that the contrast efficiency was comparable between Omniscan 
and the nanoprobe. 
2.10. Discussion 
In the current study, we show that our novel theranostic, glycogen based nanoprobe effectively and 
safely labeled several different human melanoma metastatic cell lines. Nanoprobe labeling did not 
influence the cellular behavior, labeled cells could easily be visualized in vitro with microscopy and 
MRI, and used as an effective in vivo MRI contrast agent. To our knowledge, the use of glycogen in a 
multimodal imaging nanoprobe has not been reported previously in tumor cell imaging. 
The fluorescence microscopy experiments showed that our nanoprobe was efficiently internalized 
into three different human melanoma metastatic cell lines, and the cellular uptake increased with 
elevated incubation times and doses (Figure 1). The amount of cellular internalization is commonly 
dependent on cell type, labeling time, and also on several properties of nanomaterials such as size, 
surface characteristics, morphology and charge [23–25]. Cellular uptake is reported to be dependent on 
the size of the nanoparticles, and materials around 50 nm (our nanoprobe is 54.4 nm in diameter) are 
efficiently endocytosed by cells [24,26,27]. We observed variations in fluorescence intensity and thus 
nanoprobe uptake among the three cell lines investigated. Others have also demonstrated varying 
internalization rates, using a gadolinium-based nanomaterial to label a larynx cancer cell line, a 
glioblastoma cell line and healthy lymphocytes [28]. The observed variations in cellular uptake were 
ascribed to differences in cell membrane permeability among the cell lines, which could also be the 
case in our experiments. 
The uptake of nanoprobe by the cells is likely due to a combination of nonspecific adsorptive 
endocytosis, clathrin-mediated endocytosis, macropinocytosis and dynamin-dependent endocytosis, as 
previously described for such materials [29]. These uptake mechanisms do not require specific 
receptors on the cells, and the zeta potential plays eventually an important role in the uptake. 
Molecules with positive zeta potential (our nanoprobe is weakly positive) would be more effectively 
internalized into the cells than neutral or negatively charged particles [29]. 
In general, labeling of our metastatic melanoma cell lines did not affect cell viability, indicating that 
the nanoprobe itself was not toxic to the cells (Figure 2). Labeled Melmet 5 pGF1 cells exhibited a 
slightly reduced capacity to reduce the non-fluorescent resazurin to the highly fluorescent resorufin at 
24 h. However, no differences were observed at later time-points. Melmet 1 pGF1 cells showed a 
slightly reduced viability after 72 h of incubation with the nanoprobe by the resazurin assay. It is likely 
that cells exposed to the nanoprobe may replace intracellular glycogen with the nanoprobe [22]. Our 
findings may indicate that the glucose cycle in the Melmet 1 pGF1 cell line was not as effective in 
utilizing the glycogen as well as in the other two cell lines. 
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Our nanoprobe was mainly localized in the cytoplasm of the cells, which is in agreement with other 
studies showing localization of native glycogen within mammalian cells [30]. The signal from Dy-615 
was concentrated around the nucleus and scattered throughout the cells in focal areas of varying sizes 
(Figure 3). In confocal images, co-localization between red and green stained particles would be 
observed as yellow areas. Since we commonly observed weak yellow areas in our images, a more 
thorough analysis was performed. The analysis of the subcellular localization of the nanoprobe 
demonstrated accumulation in lysosomes after 24 h. The nanoprobe was only randomly co-localized 
with the other markers investigated (Table 1). Accumulation of glycogen into lysosomes is in line with 
previous in vivo experiments on rats [31], and lysosomes have been referred to as the most common 
organelle involved in intracellular degradation of nanomaterials [26,32]. 
Our study showed a gradual clearance of the nanoprobe during 96 h (Figure 4). After 72 h,  
a relatively high amount of fluorescent signal could still be detected, indicating that therapeutic 
compounds attached to the nanoprobe in future experiments also may be internalized and exert its 
effects within the cells for several hours. Due to limitations in resolution of our confocal instruments, 
we could not investigate whether Dy-615 was still attached to the probe at this time point, or if the 
nanoprobe had been degraded inside the cytoplasm. 
Our measurements of the zeta potential showed that the nanoprobe itself exerted a relatively stable, 
very slightly positive charge (in fact nearly electroneutral—within the range ±30 mV) at different pH 
levels. According to the manufacturers information on Dyomics probes in general, the fluorescence 
intensities from these probes are not dependent on variations in pH, as the structure of carboxyl  
group-conjugated Dyomics 615 does not contain acidobasically active groups that would have pK 
close to physiological pH range 5–7.4 (the amino groups have very low basicity due to aromatic 
conjugation). Taken together, the observed decrease in fluorescence intensity over 96 h is likely not 
due to quenching of the fluorescent signal, but due to clearance of the nanoprobe from the cells. The 
nanoprobe may be entrapped within secretory vesicles in the Golgi apparatus, before being  
exocytosed by the cells [20], although we did not observe co-localization between Golgi and 
nanoprobe in our experiments. 
In addition to the suggested lysosomal degradation of the nanoprobe, we also showed that there was 
a negative correlation between the cell proliferation rate (Figure 4D) and temporal decrease in 
fluorescence intensity (Figure 4C), indicating that the observed decrease in fluorescence was also 
caused by dilution of the nanoprobe due to cell proliferation. 
There were no differences in migration between unlabeled and labeled cells. This indicates that 
cellular features such as cytoskeletal structure and cell polarization are not affected due to exposure of 
the nanoprobe [33,34]. This finding is in line with other studies investigating effects of nanomaterials 
on cancer cell lines [35]. 
The in vitro MRI study showed that we were able to detect 750 labeled cells/μL after labeling with 
200 μg/mL nanoprobe. Terreno and colleagues evaluated the number of Gd-HPDO3A labeled rat 
hepatocarcinoma cells visible by MRI in agar phantoms [36]. They incubated the cells with contrast 
agent in standard culture conditions for 16 h (5–100 mM), and showed that the minimum number of 
cells they were able to detect by MRI was 5000 cells/μL. Thus, our nanoprobe was up to 6.7 times 
more sensitive in vitro, at the concentrations we used. 
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We observed by fluorescence microscopy that a nanoprobe dose of only 10 μg/mL in the growth 
medium labeled all cells, however the fluorescence intensity was too low to be effective in further  
in vitro experiments. We did not study if other labeling concentrations would improve the detection 
limit by MRI, although it is likely that higher labeling concentrations could improve the sensitivity of 
the MRI methods. 
In vivo MRI showed that the glycogen nanoprobe increased contrast on T1 weighted images after 
administering the nanoprobe intravenously, which was comparable to what was seen after 
administering Omniscan to the same tumor. This was also confirmed by the CNR analysis. Thus, we 
demonstrated a proof-of-principle that our nanoprobe can be used as a contrast agent in MRI, in 
addition to being an excellent probe for fluorescent imaging. 
We have previously described that a 200 μm diameter brain metastasis in our animal/tumor model 
consists of around 350–400 tumor cells [4]. Here, we show that we were able to detect down to  
750 cells/μL in the agar phantoms. In our animal/brain metastasis model [34], brain lesions with a 
diameter of 300 μm would thus contain around 1300 tumor cells, and should likely be detected by T1 
weighted MRI in experiments in vivo, if successfully labeled with our nanoprobe. 
We did not investigate by ex vivo fluorescence whether the nanoprobe was internalized in the tumor 
cells in vivo, as we did not possess suitable tumor tissue for such analysis, and the main focus in this 
work was to perform a detailed in vitro characterization of the novel nanoprobe. Future studies will 
address this issue. 
Glycogen is relatively inactive to amylase present in the blood, and can thus survive transportation 
in the bloodstream without being immediately eliminated, as the molecular weight is above the renal 
threshold [22], which our FLCS study also supports. The FLCS allowed us to track the size of the 
fluorescently labeled nanoparticles even in a complex environment such as blood plasma. We observed 
that the slow-moving fraction of the fluorescence (i.e., the intact nanoprobe) did not change its 
diffusion coefficient within 60 min incubation with blood plasma, implying that the nanoprobe did not 
change its size due to degradation within this time frame. Our data, however, suggests that when the 
nanoprobe is internalized in cells, degradation within the lysosomes may occur. Due to the enhanced 
permeability and retention effects present in most tumors, the nanoprobe may be retained within tumor 
tissue for several hours after its arrival. Thus, any pharmaceuticals incorporated into the nanoprobe 
would likely be located within the tumor cells for a corresponding period of time, offering a benefit 
over conventional chemotherapeutical approaches. 
The glycogen nanoprobe would be of particular interest to us in future studies of drug delivery to 
brain metastasis in our animal brain tumor models [4,35]. The blood brain barrier (BBB) plays an 
important role in the treatment of brain metastasis, as delivery of chemotherapeutics to small tumors is 
inefficient due to an intact vascular barrier in the brain. We have previously shown that a wide variety 
of imaging tracers, with molecular weights ranging between 0.24 and 65.55 kDa, are able to leak 
across the BBB at various stages of brain metastasis development [2,4]. Even if the size of our 
nanoprobe is in the order of 10 MDa [22], further modifications of the probe by, for instance, attaching 
suitable antibodies to the surface, could facilitate receptor-mediated transcytosis of the nanoprobe 
through the vascular endothelium of the brain [37]. 
In this study, we show that two different normal human fibroblast cell lines (SV-80 and NSF3) did 
not accumulate the nanoprobe at labeling concentrations up to 100 μg/mL. This is in line with other 
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studies, which have shown that nanoparticles may accumulate to more than one order of magnitude in 
tumors compared to surrounding tissue, due to the EPR effect [20,21]. This implies that while in 
normal tissues the probe is in the vessels (in blood volume) physically separated from the surrounding 
tissue by the vessel wall, in tumor tissue it is present mainly in interstitial space in close touch with the 
tumor cells that subsequently may take up the nanoprobe. 
Uptake of nanoprobe into different animal organs, and clearance in vivo was not evaluated. Others 
have injected glycogen into rabbits and found that within a few hours, glycogen had diffused from  
the bloodstream to other organs. Further, it was suggested that glycogen used by this route of 
administration could hold a clinical value, as it was considered harmless [38]. It has been demonstrated 
previously by MRI that our glycogen nanoprobe was eliminated through the mouse kidneys. Six hours 
after intravenous injections, only a negligible amount of the nanoprobe was found within the kidney of 
the animals, which suggested minimal renal burden [22]. 
3. Experimental Section 
3.1. Glycogen Nanoprobe 
The process of synthesis as well as a detailed characterization of our glycogen nanoprobe has  
been described previously [22]. Briefly, natural glycogen was modified to an amino group-bearing 
derivative, and then it was conjugated with 0.33 wt % fluorochrome Dyomics-615-NHS ester (Dy-615) 
with a fluorescence emission maximum at 643 nm [39] and 3.19 wt % of the MRI T1 contrast agent 
gadolinium (Gd-DOTA). It was demonstrated that the nanoprobe holds a spherical shape with a mean 
diameter at 54.4 nm, has a weakly positive charge and a uniform distribution of contrast agent. 
3.2. Cell Lines and Cell Culture 
The H1 cell line was developed in our laboratory from a resected brain tumor obtained from a 
patient with metastatic melanoma [40]. The H1 cells were transduced with two lentiviral vectors, 
encoding Dendra (a GFP variant) and Luciferase, to obtain the H1_DL2 cell line [35]. The Melmet 1 
and Melmet 5 cell lines were established from human metastatic melanomas in subcutaneous tissue 
and a lymph node, respectively [41]. The Melmet 1 and Melmet 5 cells were transduced with a 
lentiviral vector, encoding CopGFP (a GFP variant, Systems Biosciences, Inc., Mountain View, CA, 
USA) and Luciferase, resulting in the Melmet 1 pGF1 and Melmet 5 pGF1 cell lines. Two normal 
human fibroblast cell lines were also used, the SV-80 lung fibroblast cell line (obtained from CLS Cell 
Line Services GmbH, Eppelheim, Germany) and the NSF3 skin fibroblast cell line (developed in our 
lab). We obtained written consent before tumor material was collected. The Regional Ethical 
Committee (#013.09) and the Norwegian Directorate of Health (#9634) approved the tissue collection 
and storage. 
All cells were grown in Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich Inc.,  
St. Louis, MO, USA) supplemented with 10% heat-inactivated newborn calf serum (Thermo Fisher 
Scientific, Waltham, MA, USA), 4 times the prescribed concentration of nonessential amino acids 
(BioWhittaker, Verviers, Belgium), 2% L-glutamine (BioWhittaker), penicillin (100 IU/mL, 
BioWhittaker), and streptomycin (100 μL/mL, BioWhittaker), hereafter referred to as complete 
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DMEM. The cells were kept in a standard tissue culture incubator at 37 °C with 100% humidity and 
5% CO2. The growth medium was exchanged twice a week. 
3.3. Cellular Internalization of the Nanoprobe 
The Melmet 1 pGF1, Melmet 5 pGF1, H1_DL2, SV-80 and NSF3 cell lines were grown in 6-well 
plates (Nunc, Roskilde, Denmark) at a density of 105 cells/mL in a total volume of 2 mL complete 
DMEM. After 24 h of incubation, the growth medium was replaced with complete DMEM containing 
the glycogen nanoprobe at final concentrations of 10, 50 or 100 μg/mL. Dishes with unlabeled cells 
were used as negative controls. After 6 or 24 h of incubation with the nanoprobe, the cells were fixed 
using 4% paraformaldehyde (PFA, Thermo Fisher Scientific) diluted in phosphate-buffered saline 
(PBS, Sigma-Aldrich). Subsequently, the cells were studied by fluorescence microscopy with a Nikon 
TE2000 inverted microscope (Nikon Instruments Inc., Melville, NY, USA) using a 20× ELWD Plan 
Fluor objective. Micrographs were acquired using the NIS Elements software (64 bit version, Nikon 
Instruments Inc.), with identical settings (gain 1.7, exposure time 600 ms) for all fluorescence images. 
The micrographs were processed using Photoshop CS5 (Adobe Systems Inc., San Jose, CA, USA). 
In a second internalization study, the three melanoma cell lines were seeded into the wells of three 
96-well plates (Nunc) at a density of 4 × 103 cells/mL in a total volume of 100 μL complete DMEM 
and incubated for 24 h. The medium was then substituted with growth medium containing the 
nanoprobe at concentrations of 100, 200, 300 or 400 μg/mL (n = 8 wells per concentration), and 
incubated for 2, 4, 6 or 24 h. Wells with unlabeled cells were used as negative controls. At the different 
time points, the wells were washed with preheated complete DMEM (37 °C), and imaged with a BD 
Pathway 855 high content imager (BD Biosciences, San Diego, CA, USA) using the 10× objective. 
The mean cellular fluorescence within each image was determined using CellProfiler v2.1.1 (Broad 
Institute, Cambridge, MA, USA). 
3.4. Cell Viability 
We performed a monolayer resazurin cell viability assay to study cell proliferation during 
incubation with the nanoprobe. The Melmet 1 pGF1, Melmet 5 pGF1 and H1_DL2 cells were each 
seeded into the wells of a 96-well dish (Nunc) at a density of 5 × 103 cells per well in 100 μL complete 
DMEM. After 24 h, the growth medium was exchanged with complete DMEM containing the 
nanoprobe in final concentrations of 100, 200, 300 or 400 μg/mL. Unlabeled cells were used as 
negative controls. After another 24 h of incubation, Resazurin solution (0.1 mg/mL, Sigma-Aldrich) 
was added at a volume corresponding to 10% of the total volume within each well. Following 
incubation for 4 h, the absorbance was measured at dual mode 560/590 nm with a scanning multiwell 
spectrophotometer (Victor 3 1420 multi-label counter, Perkin Elmer, Waltham, MA, USA), using 
WorkOut v2.0 software (Dazdaq Solutions Ltd., East Sussex, UK). This procedure was repeated on 
Days 2, 3, 4 and 5. The obtained measurements were in relative fluorescence units (RFUs) and based 
on six parallel samples. Monolayer cell viability was also determined by counting live and dead cells 
after incubating the cells with the nanoprobe. The cell lines were seeded into three six-well plates 
(Nunc) at a cell density of 1 × 105 cells/mL in 2 mL of complete DMEM. After an incubation period of 
24 h, the growth medium was replaced with complete DMEM containing nanoprobe at a concentration 
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of 200 μg/mL. Unlabeled cells were used as negative controls. The numbers of live and dead cells 
were then counted 24, 48 and 72 h after labeling, by adding 0.5 mL trypsin EDTA (BioWhittaker) and 
mixing 1:1 with growth medium. The cell numbers were determined using a Countess Automated Cell 
Counter (Invitrogen, Paisley, UK), according to the manufacturer’s instructions. The experiment was 
done in triplicate. 
3.5. Subcellular Internalization of the Nanoprobe 
We then studied whether organelles within the tumor cells were able to internalize the nanoprobe.  
In total, 5 × 104 H1 cells were distributed into five poly-L-lysine coated (Sigma-Aldrich Inc.) 25 mm 
μ-Dishes (Ibidi GmbH, Munich, Germany) and incubated for 24 h. The growth medium was then 
exchanged with 1 mL 200 μg/mL glycogen nanoprobe diluted in complete DMEM and incubated for 
another 24 h. We stained the Golgi apparatus using the following method: A 1× Assay Solution 
(Abcam ab139483, Cambridge, UK) was prepared, containing 1 mL 10× Assay Buffer 1 (Abcam),  
0.2 mL 50× Assay Buffer 2 (Abcam) and 8.8 mL milliQ water. 100 μL of this solution was then mixed 
with 50 nM Golgi Green Detection Reagent (Abcam), before 100 μL of the solution was preheated  
(37 °C) and added directly into the dish containing adhered cells. The lysosomes were stained by 
mixing 20 μL LysoGreen Indicator (Abcam ab112136) with 10 mL Live Cell Staining Buffer 
(Abcam), heated to 37 °C and 100 μL of the solution was added to the cell sample. The plasma 
membrane was stained using Wheat Germ Agglutinin (WGA), by dissolving 1 mg of Alexa Fluor® 488 
Conjugate (Thermo Fisher Scientific) in 1 mL PBS (Sigma-Aldrich), before diluting this to a working 
solution of 5 μg/mL. 100 μL of this solution was then preheated (37 °C) and added to the cell sample. 
We stained the endoplasmatic reticulum (ER) by mixing 1 mL Green Detection Reagent (Abcam 
ab139481) with 1× Assay Solution (Abcam) and adding 100 μL of this preheated (37 °C) solution to 
the cell sample. For staining of the nucleus, the cells were incubated at room temperature for 30 min in 
growth medium containing 1 μg/mL Hoechst 33342 (Life Technologies). All cells were then washed 
twice with PBS and fixed with 2 mL 4% PFA (Thermo Scientific). 
Mitochondria staining was carried out by incubating the cells with 150 nM MitoTracker® Green FM 
(Invitrogen) for 30 min before the labeling solution was replaced with complete DMEM. Live cell 
imaging was performed using a Leica TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, 
Germany), with excitation wavelengths of 408, 488 and 633 nm, and a 63× HCX PL Apo objective 
with NA 1.4. All images were processed using Imaris V 7.6.3 (Bitplane AG, Zürich, Switzerland).  
Co-localization was investigated in 3D image stacks with the co-localization plugin after the cells  
were cropped to optimal size and the auto-threshold function was applied. The Pearson’s correlation 
coefficient was measured and the average of all values for each organelle marker was determined.  
The Pearson’s correlation coefficient, R, describes the relationship in intensity distribution between 
two color channels, and the value ranges from −1 to 1. Values between −1 and 0.5 suggest  
no co-localization, R > 0.5 suggest some degree of co-localization and R = 1 suggests complete  
co-localization [42]. 
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3.6. Nanoprobe Clearance 
The Melmet 1 pGF1, Melmet 5 pGF1 and H1_DL2 cells were seeded into six-well plates at a 
density of 1 × 105 cells/mL in 2 mL complete DMEM, and incubated for 24 h. The growth medium 
was then replaced with complete DMEM containing nanoprobe at a concentration of 200 μg/mL. After 
a further incubation period of 24 h, the labeling solution was exchanged with complete DMEM 
without nanoprobe. Four micrographs of the labeled cells were captured every 24 h for four days using 
a Nikon TE2000 inverted microscope (Nikon Instruments Inc., NY, USA) with a 20× objective. In 
each micrograph, 16 single cells were processed to find the average cellular fluorescence intensity 
using Photoshop CS5 (Adobe Systems Inc., San Jose, CA, USA). 
3.7. Study of in Vitro Cell Migration 
To study the effects of the nanoprobe on cell migration, a monolayer wound healing assay was 
performed. A silicone culture insert (Ibidi GmbH, Martinsried, Germany) was positioned into each 
well of a 4-well μ-Slide (Ibidi GmbH). 70 μL of H1_DL2, Melmet 1 pGF1 and Melmet 5 pGF1 cell 
solution at a concentration of 5 × 105 cells/mL was then added into each half of the culture inserts. The 
cells were allowed to grow to confluence before the culture insert was removed, resulting in a cell free 
gap with a width of 500 μm within the culture. All chambers were washed twice with preheated  
(37 °C) complete DMEM before the chambers were filled with 500 μL growth medium containing  
200 μg/mL nanoprobe. As negative control, chambers were filled with 500 μL growth medium without 
the nanoprobe. Immediately afterwards, cell migration into the wound was studied by time lapse 
microscopy for 60 h using a Nikon TE2000 inverted microscope (Nikon Instruments Inc., Melville, 
NY, USA) equipped with an incubator holding 37 °C, 100% humidity and 5% CO2. Images were  
then processed and analyzed using ImageJ v1.46a freeware (National Institutes of Health, Bethesda,  
MA, USA). 
3.8. Measurement of Zeta-Potential 
The glycogen nanoprobe was diluted in 0.01 M phosphate buffer to obtain 0.1% (wt) solution. The 
pH of each sample was adjusted to accurate value using few microliters of diluted HCl or NaOH 
solution. Measurement was performed with Zetasizer Nano-ZS instrument (Malvern Instruments Ltd., 
Malvern, UK) that computes the zeta potential through the Henry equation. 
3.9. Measurement of Stability of the Glycogen Nanoprobe in Blood Plasma by Fluorescence Lifetime 
Correlation Spectroscopy (FLCS) 
FLCS is a variant of fluorescence correlation spectroscopy (FCS), which uses differences in rates of 
fluorescence intensity decays to obtain separate FCS autocorrelation functions (ACFs) of individual 
fluorophore populations in a mixture [43]. We used this technique to study the stability of the labeled 
glycogen nanoprobe in human blood plasma. The FLCS experiments were performed using an 
Olympus IX83 confocal laser scanning microscope with FluoView 1200 software (Olympus Corporation, 
Tokyo, Japan), extended with a FLIM/FLCS upgrade kit and SymphoTime64 software (PicoQuant 
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GmbH, Berlin, Germany). The measurements were performed with a 640 nm pulsed laser with 
repetition frequency of 40 MHz and with PMA hybrid detectors. 
First, a reference measurement of the labeled glycogen nanoprobe with a concentration of  
500 μg/mL in physiological saline was performed; Second, a measurement of human blood plasma 
(obtained from Sigma-Aldrich Ltd., Prague, Czech Republic) was performed with the same setup as 
for the reference experiment. The labeled glycogen nanoprobe and blood plasma were then mixed 
directly in a one-chamber microscope dish (with the same final nanoprobe concentration, i.e.,  
125 μg/mL). Several measurements were performed, one immediately after mixing, and then 20, 40 
and 60 min later. For the measurements in blood plasma, the FLCS curves were fitted with a two 
component model, to obtain the recovered diffusion constants. 
3.10. In Vitro MR Relaxometry 
The Melmet 1 pGF1, Melmet 5 pGF1 and H1_DL2 cells were prelabeled with nanoprobe  
(200 μg/mL) in monolayer for 24 h, as described in previous sections. A 2% Difco Agar Noble 
solution (BD, Franklin Lakes, NJ, USA) was prepared in autoclaved water, microwaved and placed  
in a preheated waterbath (50 °C). The agar solution was further mixed 1:1 with growth medium 
containing prelabeled cells. The agar/cell solution was then aliquoted into five different 2 mL 
eppendorf tubes (Eppendorf Instrumente GmbH, Hamburg, Germany), at concentrations 3000, 1500, 
750, 375 or 187 cells/μL. As negative controls, unlabeled cells were introduced into five additional  
2 mL eppendorf tubes, with the same cell concentrations as above. 
The tubes were examined at 21 °C using a 7 T small animal MRI scanner (Bruker Biospin MRI 
GmbH, Ettlingen, Germany) equipped with a 40 mm quadrature volume coil. A T2 weighted turbo spin 
echo scan was performed (repetition time (TR) 4000 ms, echo time (TE) 48 ms, field of view (FOV) 
2.0 cm, matrix size 256 × 256, slice thickness 1 mm, 15 slices, number of acquisitions (NEX) 4, axial 
sectioning) to verify homogeneity of the agar/cell solution. Then, a spin echo T1 mapping sequence 
was obtained (TR 5000, 3000, 1500, 800, 400 and 200 ms, TE 33 ms, FOV 3.5 cm, matrix size  
256 × 256, slice thickness 1 mm, 1 slice NEX 1). Within the image of each tube, a region of interest 
(ROI) covering 75% of the surface area of the tube was defined in the scan software (ParaVision 5.1), 
and T1 relaxation values of the tubes were calculated. 
3.11. Animal Model and Tumor Cell Injections 
Twelve-week-old female NOD/SCID mice were bred and maintained in animal facilities under 
standard conditions, being fed a standard pellet diet and provided water ad libitum. The National 
Animal Research Authority approved all animal procedures (Application No. 20135046, approved  
7 May 2013). 
H1_DL2 cells were cultured in 175 cm2 flasks (Nunc), trypsinated and centrifuged at 900 rpm for 
four min. The medium was removed, and the cell pellet was dissolved in PBS (Sigma-Aldrich Inc.) at 
a concentration of 107 cells/mL. The cells were kept on ice prior to injections. Two anaesthetized mice 
(2% isoflurane) were injected subcutaneously with 0.1 mL cell solution (106 cells) in their left flank or 
neck using a 30G insulin syringe (Omnican50, B. Brain Melsungen AG, Melsungen, Germany). This 
is an animal model that is already in use and thus well tested and highly standardized [4,40,44]. 
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3.12. Bioluminescence Imaging (BLI) of Tumor Development 
After 4 weeks, bioluminescence imaging (BLI) was performed to verify tumor take and growth. 
This would also suggest that contrast enhancement by MRI could be achieved after administrating the 
glycogen nanoprobe. Briefly, anaesthetized mice (2% isoflurane) were injected intraperitoneally with 
150 mg/kg D-luciferin 10 min prior to whole body imaging, performed with an Optix® MX2 Small 
Animal Molecular Imager (ART Inc., Saint-Laurent, QC, Canada). Bioluminescent images were 
acquired with Optix® OptiviewTM (ART Inc.) acquisition software (version 2.00) using an integration 
time of 0.3 s and a scan resolution of 1.5 mm, and analyzed using Optix® OptiviewTM (version 
2.00.01, ART Inc.). 
3.13. Pilot in Vivo MRI Experiment 
In vivo MRI experiments were carried out on the mice 8 weeks after tumor cell injection, at which 
time the tumor sizes were approximately 16 × 9 mm. A 7 T small animal MRI scanner (Bruker Biospin 
MRI GmbH) equipped with a 72 mm quadrature transmit coil and a mouse brain array receive coil  
was used. T2 weighted spin echo scans were initially acquired with a region of interest over the 
subcutaneous neck tumors of the mice (TR 4300 ms, TE 36 ms, FOV 2 cm, matrix size 256 × 256, 
slice thickness 1.5 mm, number of slices 25, NEX 3, axial sectioning). Tumor contrast agent uptake 
was then studied by T1 weighted spin echo scans (TR 1000/740 ms, TE 9 ms, FOV 2 cm, matrix size 
256 × 256, slice thickness 1.5 mm, number of slices 11, NEX 6, axial sectioning) before and 
immediately after administrating 0.5 μmol glycogen nanoprobe or Omniscan (GE Healthcare, 
Fairfield, CT, USA) through the tail veins. Each animal was first studied with Omniscan, and, after  
24 h, the same animal was studied using nanoprobe. T1 mapping studies were not performed, to 
minimize scan time and thus lower the burden to the animals. 
The MR images were processed using the ImageJ freeware (version 1.46r, National Institute of 
Health, Bethesda, MD, USA). Briefly, the regions of interests were carefully outlined around the area 
containing tumor excluding necrotic tissue and CNR was assessed. CNR in T1 weighted MR images 
obtained after contrast injections were calculated according to the formula: CNR = (ST − SN)/SD, 
where ST represents mean signal intensity from tumor tissue, SN means signal intensity from normal 
tissue directly outside the tumor, and SD is the standard deviation of the noise. 
3.14. Statistical Analysis 
Linear regressions and statistical analyses were performed using GraphPad Prism v7 for Mac OS X 
(GraphPad Software, Inc., La Jolla, CA, USA). Unpaired two-tailed Students t-tests were used. Values  
are presented as mean ± standard deviation (SD). For all tests, a p value < 0.05 was considered 
statistically significant. 
4. Conclusions 
In summary, we have robust data indicating that the nontoxic glycogen nanoprobe is a highly 
functional imaging probe, both for fluorescence microscopy and MRI. Our data show that the 
nanoprobe is taken up into the cytoplasm of the tumor cells, and that the probe is likely degraded 
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inside the lysosomes. We now have an excellent foundation upon which we can base further 
experiments in studies on combined therapeutic and diagnostic issues in metastatic melanoma, 
including brain metastasis. 
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